NCT00561704

Brief Summary

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2007

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2007

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 20, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 21, 2007

Completed
Last Updated

November 21, 2007

Status Verified

November 1, 2007

First QC Date

November 20, 2007

Last Update Submit

November 20, 2007

Conditions

ObeseType 2 DiabetesDiabetic NephropathyGlucose MetabolismAngiotensin II Type 1 Receptor Blockers

Keywords

obese femaleType 2 DiabetesDiabetic NephropathyGlucose MetabolismAngiotensin II Type 1 Receptor BlockersAdiponectin

Outcome Measures

Primary Outcomes (1)

  • GFR, HbA1c and the adiponectin concentration.

    6 month

Interventions

losartanDRUG

losartan, 100mg daily,

Eligibility Criteria

Age30 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetic nephropathy
  • CKD at stage 1\~4

You may not qualify if:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

ObesityDiabetes Mellitus, Type 2Diabetic Nephropathies

Interventions

Losartan

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDiabetes Complications

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsTetrazoles

Study Officials

  • hui min Jin, MD

    shanghai No 3 people's hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 20, 2007

First Posted

November 21, 2007

Study Start

April 1, 2007

Study Completion

October 1, 2007

Last Updated

November 21, 2007

Record last verified: 2007-11